INVENTURUS KNOWLEDGE SOLUTIONS LIMITED — Investor Presentation 2025

Jul 31, 2025

July 31, 2025

BSE Limited National Stock Exchange of India Limited The Listing Department The Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, Plot No. C/1, G Block, 25[th] Floor, Dalal Street Bandra Kurla Complex Fort, Mumbai 400 001 Bandra (East), Mumbai 400051 Maharashtra, India Maharashtra, India BSE Scrip Code: 544309 NSE Symbol: IKS Dear Sir/Ma’am,

Sub: Investor Presentation

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith investor presentation on the financial results of the Company for the quarter ended June 30, 2025.

The presentation is also being uploaded on the website of the Company at the - https://ikshealth.com/investor relations/

Request you to take it on record and disseminate it on your website.

Thanking you.

Yours sincerely,

For Inventurus Knowledge Solutions Limited

Sameer Digitally signed by Sameer Shashikant Shashikant Chavan Date: 2025.07.31 Chavan 22:27:09 +05'30' Sameer Chavan Company Secretary and Compliance Officer Membership No. F7211

Encl: As above

IKS Health

Q1 FY 26 Investor Presentation

==> picture [76 x 29] intentionally omitted <==

==> picture [137 x 139] intentionally omitted <==

1

Disclaimer

==> picture [75 x 29] intentionally omitted <==

This presentation may include opinions and assumptions about future performance which could be considered as forward-looking statements. Forward-looking statements intrinsically cover several risks and uncertainties, which may lead to a material difference between actual results and the statements themselves. Such statements comprise the company’s current visibility on market movements, client discussions, and related factors. Inventurus Knowledge Solutions Limited does not assume an obligation to update or revise any forward-looking statements.

2

IKS Health - a comprehensive healthcare enablement platform empowering provider organizations

==> picture [75 x 29] intentionally omitted <==

==> picture [670 x 284] intentionally omitted <==

----- Start of picture text -----

US$260bn / US$34bn
US$5tn 8% / 12%
Total TAM / Outsourced Market
US Healthcare TAM / Outsourced Market
Addressable (CY2023)
Expenditure (CY2024) CAGR (2023-2028E)
Market [1,2]
The only
Comprehensive
platform that delegates
5+ Years all chores across the
650+/750+ 95+% patient journey
Top 10 / Top 5 Clients
Established Healthcare Organizations Revenues from Repeat Average Vintage
Client Q1 26/Q1 25 Customers (As of June 30, 2025) Adding a
technology-enabled
Relationships
layer to ‘care delivery
pyramid’ to help
Physician Enterprises
12,368 / 2,260 502 64 achieve increased
Employees / Clinically Technology Focused Sales & Marketing revenue and
Specialised trained staff Employees Employees reduced expenses
workforce
(As of June 30, 2025) (As of June 30, 2025) (As of June 30, 2025)
----- End of picture text -----

Note: Numbers Rounded off to nearest Integer / percent; 1. Source: Zinnov Report; 2. TAM- Total Addressable Market for RCM, VBC, Patient, Coding and Client Services. 3. Repeat clients refers to clients who availed our platform or solutions during the previous period, and revenue generated from such clients are calculated for the relevant period

3

IKS Health enables care transformation across the patient journey

==> picture [75 x 29] intentionally omitted <==

==> picture [666 x 304] intentionally omitted <==

----- Start of picture text -----

Automation Level Automation Level Automation Level Automation Level
Optimized Patient Patient Prospective
Pre-Visit
Scheduling Financial Engagement Clinical Chart
Clearance Hub Reviews
Automation Level Automation Level Automation Level Automation Level
Tech-led Referral Order
IKS Scribble [TM] Pre-Visit Peri-Visit
Coding Management
Summary
Automation Level Automation Level Automation Level Automation Level
Post-Visit Billing & Denial Payment Concurrent & Patient AR
Prevention Posting & Denial Denovo Risk
Management
Management Coding
Automation Level Automation Level Automation Level Automation Level
Care Management Inbox IKS AssuRx [TM] IKS Stacks [TM] In-between Visits
& UM Management
Automation Level Automation Level Automation Level Automation Level Automation Level
Clinical Revenue Medico-legal
In-acute Settings Documentation Clinical Optimization Documentation Discharge
Solutions Coding & CDI Solutions Solutions Summary
----- End of picture text -----

Automation Level

==> picture [114 x 11] intentionally omitted <==

----- Start of picture text -----

1 2 3 4 5
----- End of picture text -----

4

IKS Health: 5 Strategic Pillars of execution

==> picture [75 x 29] intentionally omitted <==

==> picture [642 x 81] intentionally omitted <==

==> picture [102 x 53] intentionally omitted <==

----- Start of picture text -----

AI-native. Agentic
Platform Manifest
----- End of picture text -----

• Launched Scribble Now; launching multi-variant scribble

• Developed Autonomous Coding for two medical specialities, optimizing and expanding to other specialties

• Denial

• prediction/prevention and AI led Patient Engagement

• Establishing

• Leadership across

• AQuity Acquisition Differentiated features; while

• Integration & Growth Market driving platform

• Optimization Strategy uniqueness

• -Integration ✔✔✔ - #1 in AI-driven RCM - Secured marquee and Medical coding by platform wins in

• • Margin expansion Blackbook Independent Groups and ✔✔ - # 1 in Clinical Small/Medium Health documentation by Systems Blackbook and KLAS - Point solution Land and
• • Cross Sell motion ✔ Expand in large Health Systems

• Evolution Towards an Outcome-Oriented Company

• • Cultivating outcome-oriented deals eg WWMG that drive stickiness and additional economic pools - Building capability to drive outcomes - Palomar alignment with UC San Diego

✔✔✔- Indicates progress using a 3-point scale

5

Q1 - Strong growth while delivering continuous margin expansion

==> picture [75 x 29] intentionally omitted <==

==> picture [669 x 271] intentionally omitted <==

----- Start of picture text -----

Deep Client Globally Diversified
Growth At Scale Strong Margin Profile
Relationships Workforce
INR 7,401 mn 450+ 32% 12,368
Revenue from Enterprise level EBITDA Total Employees
Operations customers
16% INR mn 3,213/43% 20% 2,260 / 502
YoY growth in INR Revenue from Top 10 PAT Margin Clinical /tech focussed
customers employees
13% 5.54 / 5.52 years 36%/59%
45%
YoY growth in USD Top 10 / Top 5 Clients YoY growth in
Women employees
Average Vintage EBITDA/PAT
----- End of picture text -----

6

Key Client Wins

==> picture [185 x 37] intentionally omitted <==

==> picture [176 x 56] intentionally omitted <==

==> picture [176 x 41] intentionally omitted <==

==> picture [51 x 47] intentionally omitted <==

Top 5 Health System

==> picture [75 x 29] intentionally omitted <==

New partnership with Mission Community Hospital to drive financial outcomes and accountability with end-to-end revenue cycle across the hospital acute care and ambulatory surgery spaces

New partnership with Bicycle Health leveraging IKS to manage revenue cycle, enabling rapid growth and scale of the virtual network

Expanded partnership with OrthoNY to introduce IKS Virtual Clinical Assistant at a growing specialty network to take on administrative tasks and support clinical efficiencies in addition to existing RCM services.

Expanded partnership with a top 5 health system in the U.S. for coding to drive revenue performance and mitigate operational inefficiencies.

7

IKS Investment in WWMG MSO - Deal Overview

==> picture [75 x 29] intentionally omitted <==

WWMG Key Metrics Investment Structure

$91M

90+

Annual Revenue Clinicians

30+ 20 Years of Experience Specialities

Investment Amount: $17M MSO Shareholding: 48% Pre-money Valuation: $18.4M Revenue Share to MSO: 62.6%

Transaction Structure

WWMG will split into a dual structure Professional Corporation (the Practice) for clinical staff and the MSO for non-clinical aspects. MSO will oversee all non clinical operations of the practice where IKS has a 48% stake and an operating agreement.

8

Strategic Value & Expected Outcomes

==> picture [75 x 29] intentionally omitted <==

IKS 3.0 Evolution

From Platform Provider to Transformation Partner

==> picture [641 x 158] intentionally omitted <==

----- Start of picture text -----

Revenue Enhancement Cost Reduction Growth Opportunities
● 2% upside from reducing revenue ● 30-40% reduction in revenue cycle ● Value-based care: +124 patients per
cycle leakages costs PCP
● 1.5-2% visit increase through ● 20% reduction in MA costs ● 8% increase in RAF scores
referral management ● 10% reduction in medical records ● 6% reduction in Medical Cost Ratio
● 10% productivity gain from clinical costs (MCR)
documentation
● 1% productivity gain from Virtual
Clinical Assistant
----- End of picture text -----

✓ Advances IKS up the value chain

✓ Creates sustainable physician aggregation model

✓ Deepens platform stickiness with a 30 year auto renew contract

✓ Enables capital-light growth model

9

Awards and Recognition

==> picture [203 x 116] intentionally omitted <==

KS Health BW Best CFO & Finance Strategy Excellence Awards 2025I

Excellence in Mergers and Acquisitions (Organizational Category)

Best Woman CFO - Nithya Balasubramanian (Individual Category)

==> picture [209 x 161] intentionally omitted <==

3rd Edition of the ET HR World Employee Experience Awards 2025 Exceptional Employee Experience (Large Scale Enterprise Category)

==> picture [75 x 29] intentionally omitted <==

10

Q1 FY 26: Growing faster than market with improving margins

==> picture [75 x 29] intentionally omitted <==

==> picture [605 x 334] intentionally omitted <==

----- Start of picture text -----

Revenue EBITDA
INR Mn INR Mn
2,378
2,262
7,240 7,401 15.6% YoY 36.3% YoY
6,401
1,745
32.1%
2.2% QoQ 31.2% 5.1% QoQ
27.3%
Q1 FY25 Q4 FY25 Q1 FY26 Q1 FY25 Q4 FY25 Q1 FY26
PAT
Adjusted PAT
INR Mn
INR Mn
1,646 1,682
58.7% YoY
51.4% YoY
1,478 1,515
1,111
955 22.7%
20.5%
20.4% 2.5% QoQ 22.7%
2.2% QoQ
14.9% 17.4%
Q1 FY25 Q4 FY25 Q1 FY26 Q1 FY25 Q4 FY25 Q1 FY26
----- End of picture text -----*

*Adjusted PAT is adjusted for amortization of intangible assets recognised on acquisition which is a non-cash expense

11

Q1 FY 26 - Improving EPS and maintaining high ROE

==> picture [75 x 29] intentionally omitted <==

==> picture [231 x 269] intentionally omitted <==

----- Start of picture text -----

EPS ₹
57.7% YoY
2.0% QoQ
----- End of picture text -----

==> picture [216 x 269] intentionally omitted <==

----- Start of picture text -----

ROE %
----- End of picture text -----

EPS is calculated as profit for the period divided by weighted average number of equity shares as defined in IND AS 33.

Return on Equity is calculated as profit for the period divided by total equity at the end of the period.

12

Q1 FY 26 - Continued strong cash generation supporting growth aspirations

==> picture [139 x 31] intentionally omitted <==

----- Start of picture text -----

Net Debt
INR Mn
----- End of picture text -----

OCF & FCF INR Mn

==> picture [75 x 29] intentionally omitted <==

==> picture [76 x 67] intentionally omitted <==

----- Start of picture text -----

23.4% OCF
27.0% FCF
----- End of picture text -----

Reported OCF and FCF are impacted by upfront guarantee payment of economic value add made to a new customer $5 million or INR 428 million

13

Particulars	Q1 FY 26	Q4 FY 25	QoQ%	Q1 FY 25	YoY%
Revenue USD mn	87	84	3.0%	77	13.2%
Revenue	7,401	7,240	2.2%	6,401	15.6%
Other Income - Operating*	-	-	0.0%	34*	0.0%
Forex Gain/ (Loss)	12	(24)	-148.8%	4	178.7%
Employee benefit expense excluding ESOP	3,871	3,749	3.2%	3,564	8.6%
Other Expenses	1,075	1,089	-1.2%	1,087	-1.1%
Adjusted EBITDA	2,467	2,378	3.7%	1,788	37.9%
Adjusted EBITDA %	33.3%	32.8%	0.5%	27.9%	5.4%
ESOP Cost	89	116	-23.7%	44	102.3%
EBITDA	2,378	2,262	5.1%	1,745	36.3%
EBITDA %	32.1%	31.2%	0.9%	27.3%	4.9%
Finance cost	181	210	-14.0%	260	-30.4%
Depreciation and amortisation	279	283	-1.5%	282	-1.2%
Interest income	31	33	-5.5%	21	45.7%
Profit before exceptional items and tax	1,949	1,801	8.2%	1,223	59.3%
Profit before exceptional items and tax %	26.3%	24.9%	1.5%	19.1%	7.2%
Tax expense	433	323	34.3%	269	61.4%
Profit for the period	1,515	1,478	2.5%	955	58.7%
Profit for the period %	20.5%	20.4%	0.1%	14.9%	5.6%
Amortisation of Intangible assets	167	168	-0.6%	156	6.7%
Adjusted Profit for the period	1,682	1,646	2.2%	1,111	51.4%
Adjusted Profit for the period %	22.7%	22.7%	0.0%	17.4%	5.4%

14

Other KPI Metrics
Particulars						Q1 FY 26	Q4 FY 25	Q1 FY 25
Annualised Adjusted EBITDA per employee in INR mn						0.81	0.76	0.53
Revenue from Top 10 customers INR mn						3,213	2,842	2,211
Contribution	from Top 10 customers					43.4%	39.3%	34.5%
Revenue from Top 5 customers INR mn						2,349	1,944	1,403
Contribution	from Top 5 customers					31.7%	26.9%	21.9%
Ageing of Top 10 clients (number of years)						5.54	6.23	6.34
Ageing of Top 5 clients (number of years)						5.52	5.67	6.55

15

Dr. Garheng Kong, MD | PhD | MBA – Board of Director Nominee

==> picture [75 x 29] intentionally omitted <==

==> picture [29 x 57] intentionally omitted <==

Experience

• Founder & Managing Partner, HealthQuest Capital

• 36 IPO/M&A exits

• Lead Independent Director, Labcorp

• Boards: Xeris Biopharma, Be The Match, Duke University Health System

• Former Partner at Intersouth & Sofinnova; roles at GSK, McKinsey

Credentials & Education

• Dual BS – Chemical Engg & Biological Sciences, Stanford University

• ● MD, PhD (Biomedical Engg) & MBA, Duke University

• Aspen Institute Health Innovators Fellow; Kauffman Fellows Mentor

• Top 25 Healthcare Investor (GrowthCap 2022).

Why He’s an Ideal Fit

• Deep Financial Acumen

• Healthcare & Strategy Insight

• Independent and Governance Track Record

• Global Network & Capital Markets Credibility

==> picture [249 x 276] intentionally omitted <==

16

==> picture [139 x 140] intentionally omitted <==

Join the Movement Grow, Scale, Thrive

==> picture [720 x 63] intentionally omitted <==